-
Update points of the guidelines for the diagnosis and treatment of hematological malignancies 2022 CSCO guidelines
Time of Update: 2022-06-03
Chronic lymphocytic leukemia (CLL) >>>> newly treated patients with indications for treatment, no del(17p)/TP53 gene mutation, and severe concomitant diseases (CIRS score > 6 points) Level I recommendation: increase " Zanubrutinib" .
-
Zhang Feng's CRISPR gene-editing drug has been awarded the title of rare pediatric disease again, and is expected to cure β-thalassemia at one time
Time of Update: 2022-06-01
Recommended reading: ASH2019: Sangamo Announces Phase 1/2 Clinical Data for β-Thalassemia, New Gene Editing Cell Therapy Worth Further Exploration Zi's autologous CD34+ hematopoietic stem and progenitor cell injection is an autologous, in vitro gene editing cell therapy research product in clinical development for the treatment of transfusion-dependent β-thalassemia .
-
BJH: Efficacy and safety of bendamustine combined with pomalidomide and dexamethasone triple therapy in patients with RRMM who have received two or more drugs
Time of Update: 2022-05-26
In this phase II study, researchers investigated the efficacy and safety of bendamustine in combination with pomalidomide and dexamethasone in patients with RRMM who had received two or more medications .
-
Universal CAR-NK for relapsed/refractory acute myeloid leukemia (AML), 3/5 cases achieved CR
Time of Update: 2022-05-25
The most intriguing clinical data is that high-dose ( 10x108 or 15x108 CAR -NK cells, 3 infusions) showed a good response in AML, with 3 CRs in 5 subjects, of which 2 had minimal MRD.
-
BJH: Can nivolumab alone cure patients with relapsed or refractory Hodgkin lymphoma?
Time of Update: 2022-05-25
It has been suggested that younger patients with early and deep responses are more likely to be relapse-free 1 year after anti-PD-1 discontinuation .
It has been suggested that younger patients with early and deep responses are more likely to be relapse-free 1 year after anti-PD-1 discontinuation .
-
Universal CAR-NK for relapsed/refractory B-cell lymphoma, 3/6 cases achieved CR
Time of Update: 2022-05-25
On April 25, U. S. time, Nkarta Therapeutic (later known as Nkarta) announced the latest clinical data on the company’s two CAR-NK pipelines, NKX101 (targeting NKG2D) and NKX019 (targeting CD19), in
-
Ann Med: Outcomes in adolescents and young adults with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Time of Update: 2022-05-25
MMR: major molecular response; DMR: deep molecular response; TKI: tyrosine kinase inhibitorIn AYA patients, peripheral blood (PB) white blood cell counts and percentage of blasts were significantly elevated at diagnosis, hemoglobin levels were lower, and spleens were larger .
-
Ann Hematol: Daily oral iron supplementation versus alternate-day therapy in women of reproductive age with iron deficiency anemia
Time of Update: 2022-05-25
Comparison of daily oral iron replacement therapy with every other day treatment in female reproductive age patients with iron-deficiency anemia .
Comparison of daily oral iron replacement therapy with every other day treatment in female reproductive age patients with iron-deficiency anemia .
-
JHBPS: Relationship between red blood cell distribution width and blood transfusion in living donor liver transplant patients: a propensity score analysis
Time of Update: 2022-05-25
Figure 1: ROC curve of red blood cell distribution width during intraoperative blood transfusion in living donor liver transplant patients
(2022), Association between red blood cell distribution width and blood transfusion in patients undergoing living donor liver transplantation: propensity score analysis.
-
Lancet Haematol: Jin Jie / Zhu Honghu team used Veneclax + DA regimen to treat AML, the first CR was as high as 91%
Time of Update: 2022-05-25
Of the 7 RUNX1-RUNX1T1 patients, 2 had a 3 log decrease in molecular levels after one course of DAV induction therapy, and 4 achieved complete molecular remission (CMR) (<0.
-
Leukemia: Efficacy and Safety of Guadecitabine in Patients with Peripheral T-Cell Lymphoma
Time of Update: 2022-05-22
RHOAG17V mutation is associated with prolonged progression-free survivalIn conclusion, Guadecitabine demonstrated acceptable overall response rates and toxicity profiles in patients with peripheral T-cell lymphoma ; decitabine analogs may be promising candidates for future combined targeting of histone methyltransferases.
-
Transplant Cell Ther: Post-transplant Cyclophosphamide Therapy and Total Bone Marrow and Lymphatic Irradiation as a Conditioning Protocol Test in Patients with AML in Remission
Time of Update: 2022-05-21
2000 cGy of total bone marrow and lymphoid irradiation (TMLI) and post-transplant cyclophosphamide (PTCy) are used in acute myeloid leukemia patients with first or second CR to reduce the risk of chronic GVHD by using PTCy while at the same time.
-
J Clin Oncol: Efficacy and safety of nasoprilumab in the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy
Time of Update: 2022-05-21
This study is a single-arm, open-label, flight trial to evaluate the safety and efficacy of nasoprilumab in adult patients with HSCT-TMA .
A single-arm, open-label flight trial to evaluate the safety and efficacy of nasoprilumab in adult patients with HSCT-TMA .
-
Bmc Infect Dis: Systemic Antifungal Strategies in Allogeneic Hematopoietic Stem Cell Recipients: Analysis of a Cross-sectional Observational AFHEM Study
Time of Update: 2022-05-21
The literature reported here analyzes a cross-sectional observational AFHEM study to describe the use of antifungal drugs in real-world clinical practice in alloHSCT recipients hospitalized in a French hematology ward .
-
NEJM: Announced Phase 3 Study Results of Ivornib Combined with Azacitidine in IDH1 Mutant AML, Significant Patient Benefit
Time of Update: 2022-05-19
Acute myeloid leukemia (AML) mainly affects the elderly (median age 68 years), and elderly patients and patients who cannot tolerate intensive induction chemotherapy (so-called unfit patients) can receive low-intensity non-curative regimens (such as low-dose cytidine and demethylating drugs), while in unfit patients with acute myeloid leukemia of unknown mutation status, azacitidine combined with venetoclax improved overall survival .
-
Does human serum albumin enhance immunity?
Time of Update: 2022-05-19
Unreasonable clinical applications include nutritional supplements, nephrotic syndrome, and chronic liver cirrhosis .
Unreasonable clinical applications include nutritional supplements, nephrotic syndrome, and chronic liver cirrhosis .
Unreasonable clinical applications include nutritional supplements, nephrotic syndrome, and chronic liver cirrhosis .
-
Reflection caused by only 0.5% of slit nucleus lymphocytes seen in bone marrow
Time of Update: 2022-05-19
When slit nucleus lymphocytes are seen in peripheral blood or bone marrow, it is necessary to combine clinical and other relevant examinations, and communicate with clinicians in time to provide reliable clinical evidence.
-
Uric acid less than 1 μmol/L?
Time of Update: 2022-05-19
Looking at the reagent instructions, vitamin C and cold and fever drugs such as acetaminophen and analgin will affect the uric acid detection; long-term vegetarians and extremely malnourished people also Temporary hypouricemia may occur; familial hereditary uric acid synthesis disorder or increased excretion is the main cause of hypouricemia; in order to further understand the situation, the author contacted the patient by phone .
-
The first subject of Boshengji PA3-17 injection phase I clinical reinfusion
Time of Update: 2022-05-19
The autologous CD7-CAR-T cell injection independently developed by the company is of great clinical value for the treatment of refractory and relapsed T-cell and NK-cell malignancies .
-
The latest guidelines ACR & EULAR jointly issued new classification criteria for granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with vasculitis
Time of Update: 2022-05-17
Vascular Arthritis & Rheumatology Annals of Rheumatic DiseasesDiagnosis 1eosinophilic granulomatosis with polyangiitis 107 cases of EGPA and 450 controls were included in the development of the EGPA classification criteria .
1136/annrheumdis-2021-221794 2granulomatosis with polyangiitis Granulomatosis with polyangiitis (GPA) classification criteria included 578 GPA cases and 652 comparators .
